Skip to main content Skip to megamenu (after main content)
Meet us next:   BIO International Convention 2025 – 16-19 June 2025  ●  more on our events calendar

Corporate News

Page (5)

PRESS RELEASE: ABLE Biott Bioreactors now available in Europe

22 August 2019

REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.

REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders

13 May 2019

REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.

REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy

24 April 2019

REPROCELL India and Hanugen Therapeutics have announced the launch of their custom manufacture offering for synthesis of milli molar scale clinical grade oligonucleotides for gene therapy.

REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification

08 April 2019

Find out about REPROCELL USA's recently achieved ISO9001:2015 accreditation. demonstrating its ability to consistently meet customer requirements

UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine

14 March 2019

Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.

REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development

12 March 2019

REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.

REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories

28 February 2019

REPROCELL Inc. and Fox Chase, Ltd., have formed a joint venture to begin operations of multi-site biosample repository facilities globally.

Appointment of New Distributor in China

01 February 2019

The REPROCELL group has signed non-exclusive distributorship agreement with RUITAI Biotechnology (Shanghai) Ltd to distribute REPROCELL’s group products in China.

ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

10 October 2018

Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production

REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER

09 October 2018

REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan).

Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan

01 August 2018

Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

21 June 2018

Read more about how REPROCELL’s BioServe and Biopta tissue procurement networks have combined to create a new service isolating human primary cells.

REPROCELL’s footprint extends to serve life sciences in India

13 June 2018

Learn more about REPROCELL India's expansion into the life sciences industry through the integration of Oligonucleotide Services and Next Generation Sequencing

Acquisition of BioServe Biotechnologies India Pvt. Ltd.

26 April 2018

REPROCELL announces that it has acquired Bioserve biotechnologies, further expanding REPROCELL's portfolio of service offerings

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

18 April 2018

REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.

Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow

06 April 2018

Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017

REPROCELL’s David Bunton addresses the Scottish Parliament

21 March 2018

Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.

Patient-derived tumor organoids recapitulate clinical treatments

14 March 2018

REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.

REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018

24 January 2018

Read the announcement that REPROCELL Europe’s CSO Prof Stefan Przyborski will chair the first day of the 3D Cell Culture conference.

Formation of human tissue to improve drug testing and reduce animal research

19 January 2018

REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday.